STOCK TITAN

Bruker Corporation - BRKR STOCK NEWS

Welcome to our dedicated page for Bruker Corporation news (Ticker: BRKR), a resource for investors and traders seeking the latest updates and insights on Bruker Corporation stock.

Bruker Corporation (symbol: BRKR) stands as a global leader in analytical instrumentation. With over fifty years of innovation, Bruker aims to provide top-tier technological solutions for various analytical tasks. Headquartered in Massachusetts, USA, Bruker employs more than 6,500 individuals across 90 locations worldwide.

The company's operations are categorized into four main segments:

  • BSI BioSpin: Specializes in magnetic resonance technologies, including NMR, EPR, and preclinical MRI systems.
  • BSI CALID: Focuses on mass spectrometry, chromatography, molecular spectroscopy, and in vitro diagnostics.
  • BSI Nano: Offers solutions in X-ray diffraction, elemental analysis, atomic force microscopy, and surface and dimensional metrology.
  • Bruker Energy & Supercon Technologies (BEST): Provides superconducting materials and devices for energy, science, and healthcare sectors.

Bruker demonstrates a strong commitment to research and development, continuously expanding its suite of products and maintaining a robust installed base globally. The company’s dedication to quality and reliability is reflected in its significant presence in the Asia Pacific region, which accounts for the largest share of its revenue.

Recent achievements include advancements in mass spectrometry and collaborations with leading pharmaceutical and biotechnology companies. Bruker's technologies are vital for quality assurance in industrial production processes, supporting customers in ensuring precision and reliability.

Bruker Corporation is not just a manufacturer but a partner in innovation, helping scientists and researchers address complex analytical challenges with integrity and cutting-edge technology.

Rhea-AI Summary

Bruker (Nasdaq: BRKR) announced the suspension of an injunction affecting sales of CosMx™ Spatial Molecular Imager (SMI) products by its NanoString business in Germany. This development is related to ongoing patent litigation with 10x Genomics. The suspension was made possible after Bruker posted a bond authorized by the Munich Higher Regional Court.

The German Higher Regional Court of Munich had previously granted NanoString the right to lift the injunction, citing concerns with the lower Munich Regional Court's May 2023 decision. The Court noted that the lower court had failed to address relevant aspects of the case, including a disputed feature of the patent at issue.

As a result, all CosMx products are now available again to German scientific instrument customers, effective immediately.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.45%
Tags
none
-
Rhea-AI Summary

Bruker (Nasdaq: BRKR) has successfully installed a 1.2 GHz NMR spectrometer at the Leibniz Forschungsinstitut für Molekulare Pharmakologie (FMP) in Berlin, accepted in Q2 2024. This advanced system will significantly enhance research capabilities in structural biology, pharmacology, and cellular biology by providing detailed insights into biomolecular structures and functions. The 1.2 GHz NMR system is expected to enable significant advancements in the understanding of intrinsically disordered proteins, which play critical roles in diseases like cancer and infectious diseases. It will support the characterization of novel active compounds and mechanisms of action, aiding in drug development efforts. FMP is already equipped with eleven NMR systems, and this latest addition marks a substantial evolution in its research capabilities. Key figures at FMP, including Dr. Peter Schmieder and Professors Hartmut Oschkinat and Adam Lange, emphasize the transformative potential of this technology in their research endeavors. Bruker expresses its commitment to supporting groundbreaking discoveries at FMP.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.11%
Tags
none
-
Rhea-AI Summary

Cellens, an early-stage cancer diagnostic company, announced a collaboration with Bruker BioAFM to develop the first clinical diagnostic tests using multi-parametric, single-cell biophysical markers and machine learning. Utilizing Bruker's advanced atomic force microscopy, Cellens aims to detect bladder cancer through non-invasive urine tests. The technology has shown high sensitivity and specificity in pilot studies. This collaboration seeks to address the unmet challenges in detecting and monitoring bladder cancer and to improve patient compliance and access to care. The platform may extend to other cancers, providing a non-invasive, cost-effective alternative to current standards.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.75%
Tags
none
Rhea-AI Summary

Bruker Applied Mass Spectrometry Division has unveiled new high-performance solutions at ASMS 2024, including the EVOQ® DART-TQ⁺ and ecTOF™ mass spectrometers. The EVOQ® DART-TQ⁺, a chromatography-free triple-quadrupole mass spectrometer, significantly reduces analysis times to 20 seconds per sample and cuts costs. It also offers an easy switch to LC-MS mode for water and food testing. The ecTOF™ system, a compact time-of-flight mass spectrometer, provides high-resolution GC-HRMS with simultaneous EI and CI ionization, enhancing compound identification and reducing false positives. These innovations aim to improve productivity, lower operational costs, and increase data accuracy for applied markets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.53%
Tags
none
-
Rhea-AI Summary

Bruker announced the release of the neofleX Imaging Profiler MALDI-TOF/TOF system, enhancing mass spectrometry imaging for tissue research. The neofleX, featuring a 10 kHz smartbeam 3D laser, offers high pixel fidelity and robust performance in various modes. It supports multiomics MSI, correlating proteins with glycans, metabolites, and now mRNA/DNA.

At the ASMS 2024 conference, researchers demonstrated the system's capability, mapping 116 proteins in a lung tissue section in 7 hours. The neofleX is compatible with MALDI-ISH and HiPLEX-IHC technologies, enhancing spatial biology research in fields like oncology and neuroscience.

The system's SCiLS Scope software facilitates easy data output and visualization, promoting collaboration in translational research.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.53%
Tags
none
-
Rhea-AI Summary

Bruker has introduced the timsTOF Ultra 2, a highly sensitive system for advanced 4D-Proteomics, at the ASMS 2024 meeting. This system significantly enhances the ability to profile small cells and subcellular organelles, identifying and quantifying up to 50% more protein groups and 100% more peptides with very low sample amounts. The new Spectronaut 19 software further improves data analysis, enabling better protein quantitation. Bruker also launched the OmniScape software for top-down proteoform analysis and GlycoScape for real-time glycoproteomic data processing. The company has started shipping over 1,000 timsTOF systems, marking a significant milestone. Additionally, the new ENRICHplus kit from PreOmics offers a 7-fold improvement in plasma proteomics, highlighting the robustness of the timsTOF HT system.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.53%
Tags
none
Rhea-AI Summary

Bruker (Nasdaq: BRKR) has announced its participation in two upcoming investor conferences: the 2024 Jefferies Global Healthcare Conference on June 6, 2024, in New York, NY, and the 45th Annual Goldman Sachs Global Healthcare Conference on June 12, 2024, in Miami, FL.

The company's top executives, including Chairman and CEO Frank Laukien and CFO Gerald Herman, will deliver presentations. Live audio webcasts of both events will be available on Bruker's Investor Relations website.

Replays of the presentations will also be accessible for at least 30 days post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.53%
Tags
conferences
-
Rhea-AI Summary

Bruker (Nasdaq: BRKR) has announced the pricing of its public offering of 6,000,000 shares of common stock. The underwriters have a 30-day option to purchase an additional 900,000 shares. The offering is expected to close by May 31, 2024, subject to customary conditions. Proceeds will be used to reduce debt from recent acquisitions, including repaying borrowings under the amended revolving credit agreement dated January 18, 2024. BofA Securities and J.P. Morgan are the joint underwriters. The shares may be sold on the Nasdaq Global Select Market or other venues at prevailing or negotiated prices. A final prospectus will be filed with the SEC.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.66%
Tags
-
Rhea-AI Summary

Bruker (Nasdaq: BRKR) has announced a public offering of 6,000,000 shares of its common stock. The company may offer an additional 900,000 shares within 30 days based on the underwriters' decision.

The offering, managed by BofA Securities and J.P. Morgan, aims to reduce Bruker's indebtedness following recent acquisitions, specifically repaying part of its borrowings under a revolving credit agreement dated January 18, 2024.

The offering is contingent on market conditions and other customary closing requirements, with no guarantee on its completion or terms. A registration statement has been filed with the SEC and the final prospectus will be available once filed.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.66%
Tags
Rhea-AI Summary

Bruker (Nasdaq: BRKR) will host an Investor Webinar on May 17, 2024, from 10 am to 12 noon EDT. The webinar will cover Bruker’s three recent acquisitions: Chemspeed, ELITech, and the NanoString business. Presentations will be given by CEO Frank H. Laukien, CFO Gerald Herman, and leaders of the new acquisitions. A medium-term financial outlook update will also be provided. The event will include a live Q&A session for analysts and investors. Webinar access details will be available on Bruker’s Investor Relations website, with a replay available post-event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.18%
Tags
none

FAQ

What does Bruker Corporation specialize in?

Bruker Corporation specializes in analytical instrumentation, offering solutions in magnetic resonance, mass spectrometry, X-ray analysis, and superconducting technologies.

How is Bruker Corporation structured?

Bruker operates in four main segments: BSI BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies (BEST).

Where does Bruker generate most of its revenue?

The majority of Bruker's revenue is generated from the Asia Pacific region.

How many employees does Bruker Corporation have?

Bruker Corporation employs over 6,500 people globally.

What industries does Bruker serve?

Bruker serves the life sciences, pharmaceutical, biotechnology, and industrial production sectors.

What recent advancements has Bruker made?

Bruker has made significant advancements in mass spectrometry and has formed key partnerships with leading pharmaceutical and biotechnology firms.

What is BSI BioSpin known for?

BSI BioSpin is known for its magnetic resonance technologies, including NMR, EPR, and preclinical MRI systems.

Why are Bruker's technologies important in industrial production?

Bruker's instruments ensure quality and process reliability, which are critical for precision and performance in industrial production.

What is the BEST segment of Bruker Corporation?

BEST, or Bruker Energy & Supercon Technologies, provides superconducting materials and devices for the energy, science, and healthcare sectors.

How does Bruker Corporation contribute to scientific research?

Bruker develops state-of-the-art technologies that assist scientists and researchers in addressing complex analytical questions with precision.

Bruker Corporation

Nasdaq:BRKR

BRKR Rankings

BRKR Stock Data

9.37B
151.34M
31.86%
74.42%
1.72%
Analytical Laboratory Instrument Manufacturing
Manufacturing
Link
United States of America
BILLERICA